Sunil Healthcare Ltd

Sunil Healthcare Ltd has been downgraded from a Sell to a Strong Sell rating as of 5 June 2026, reflecting deteriorating technical indicators and persistently weak financial fundamentals. The pharmaceutical micro-cap’s current Mojo Score stands at 26.0, underscoring significant concerns across quality, valuation, financial trends, and technicals that have prompted this decisive rating change.

Sunil Healthcare Limited, India's second-largest manufacturer of empty hard gelatin capsules, reported a remarkable turnaround in profitability for Q4 FY26, posting a net profit of ₹1.52 crores—a dramatic 322.22% surge year-on-year from ₹0.36 crores in Q4 FY25. However, this earnings recovery came against a backdrop of declining revenues, with quarterly sales dropping 6.98% YoY to ₹19.72 crores, raising questions about the sustainability of this profitability rebound. The stock, trading at ₹63.50 with a market capitalisation of ₹67.00 crores, has declined 6.19% following the results announcement, reflecting investor scepticism about the company's growth trajectory.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 May 2026, providing investors with the latest insights into its performance and outlook.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Apr 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sunil Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 13 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the second consecutive session, Sunil Healthcare Ltd has seen its share price decline sharply, hitting a fresh 52-week low of Rs 56.35 on 7 Apr 2026 despite opening the day with a gap-up. This renewed weakness comes amid heightened volatility and a broader market environment that has not favoured the stock’s micro-cap status.

For the fourth consecutive session, Sunil Healthcare Ltd closed lower, culminating in a fresh 52-week low of Rs 58.1 on 2 Apr 2026. This decline comes despite an intraday high of Rs 64.5, reflecting significant volatility and persistent selling pressure.

Sunil Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 1 April 2026. This change reflects a nuanced improvement in valuation metrics and financial trends, despite ongoing challenges in quality and technical indicators. The company’s Mojo Score now stands at 32.0, signalling a cautious but more favourable outlook compared to its previous standing.

Sunil Healthcare Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 23 March 2026, reflecting a complex interplay of valuation improvements, financial trends, quality concerns and technical indicators. Despite some positive quarterly results and an attractive valuation profile, the company’s weak long-term fundamentals and underperformance relative to the broader market have weighed heavily on investor sentiment.

Sunil Healthcare Ltd’s stock declined sharply to a fresh 52-week low of Rs.58.4 today, marking a significant downturn amid a volatile trading session and broader market pressures. The stock’s performance contrasts with the modest recovery seen in the Sensex, underscoring sector-specific and company-level challenges.

Sunil Healthcare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 18 Mar 2026, driven primarily by a marked improvement in valuation metrics and positive financial trends. Despite lingering concerns over long-term fundamentals and market underperformance, the company’s very attractive valuation and recent quarterly results have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Sunil Healthcare Ltd has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a challenging recent performance relative to the Sensex. This change is driven by improved price-to-earnings and price-to-book value metrics, signalling potential value for investors amid a micro-cap pharmaceutical sector landscape.

Sunil Healthcare Ltd’s shares declined to a fresh 52-week low of Rs.58.61 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has experienced sustained pressure over recent sessions, reflecting a combination of subdued financial metrics and broader market dynamics.

Sunil Healthcare Ltd’s shares declined sharply to a new 52-week low of Rs.59 on 16 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and market sentiment.